How Marijuana Legalization Affected OrganiGram and Aphria’s Latest Results
How Marijuana Legalization Affected OrganiGram and Aphria’s Latest Results ,These two marijuana stocks reported very different results last quarter. Plus, how Abbott’s challenging Dexcom in diabetes, and what’s next for Bristol-Myers following its Celgene acquisition.
Marijuana companies OrganiGram and Aphria reported their most recent quarterly earnings earlier this week. One of the companies reported surprisingly strong sales, while the other delivered disappointment. Are these marijuana stocks buys?
In this episode of The Motley Fool’s Industry Focus: Healthcare, analysts Shannon Jones and Todd Campbell explain how these companies. Are performing and what could be next for investors. Shannon and Todd also discuss why Abbott Labs is locking horns with Dexcom in diabetes and what the future looks like for Bristol-Myers Squibb, now that its acquisition of Celgene is official.
To catch full episodes of all The Motley Fool’s free podcasts, check out our podcast center. A full transcript follows the video.
Here’s The Marijuana Stock You’ve Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming.
Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.
And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.
Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.
Simply click here to get the full story now.